O
Overview
OriGene Technologies provides gene-based research tools and reagents for academic, pharmaceutical, and biotech researchers. It sells cDNA clones, antibodies, proteins, RNAi, and lentiviral particles directly to research institutions worldwide. It differentiates itself with a very large inventory and a distributed manufacturing network that enables rapid access to a broad set of gene-based tools. Its goal is to help researchers advance gene-based science by providing reliable reagents and educational resources.
Work here?Claim your company
Simplify's Take
What believers are saying
- OriGene launched EV Isolation Reagent and CD9 Exosome ELISA on March 23, 2026.
- Its August 2026 site highlights broad Simple Western antibody coverage in EV, AAV, oncology.
- The November 2025 ProteanFect distributorship adds transfection exposure beyond catalog reagents.
What critics are saying
- August 31, 2026 image-integrity review exposed 2,236 flagged validation images, hurting trust.
- Nature’s August 25, 2026 report linked OriGene to widespread antibody-image manipulation scrutiny.
- If validation credibility erodes, academic buyers switch to Abcam, Thermo Fisher, and Bio-Techne.
What makes OriGene Technologies unique
- OriGene’s September 2026 catalog lists 1,138,382 products across clones, antibodies, proteins.
- Its June 2025 capability page claims 586K full-length human cDNA clones.
- KO validation and Simple Western-optimized antibodies anchor its validation-heavy selling proposition.
Help us improve and share your feedback! Did you find this helpful?
Funding
Notable Investors:
Late VC funding comparison data is currently unavailable. We're working to provide this information soon!
Late VC Funding Comparison